Incremento de supervivencia en melanoma - page 12

Nivolumab in BRAF WT melanoma:

Response

ORR 42.9%

ORR 14.4%

Atkinson et al. SMR 2015

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,2,3,4,5,6,7,8,9,10,11 13,14,15,16,17,18,19,20,21,22,...29